Compare AGBK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGBK | COLL |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2025 | 2015 |
| Metric | AGBK | COLL |
|---|---|---|
| Price | $5.88 | $22.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $17.20 | ★ $51.40 |
| AVG Volume (30 Days) | 155.2K | ★ 848.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $235.22 | N/A |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $5.73 | $21.65 |
| 52 Week High | $12.21 | $50.79 |
| Indicator | AGBK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 32.19 |
| Support Level | N/A | $21.65 |
| Resistance Level | $7.42 | $35.33 |
| Average True Range (ATR) | 0.21 | 0.89 |
| MACD | -0.07 | 0.30 |
| Stochastic Oscillator | 10.14 | 40.85 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.